Immunotherapy
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
84
NCT01347996
Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
Phase: Phase 4
Role: Lead Sponsor
Start: Jul 31, 2009
Completion: Jun 30, 2014
Loading map...